Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.91 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.88 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.70 |
| ▸ | KLK7 | P49862 | 1/20 | 0.68 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL580605 | 0.98 | GAA (0.88) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL7918570 | 0.94 | NPSR1 (1.00) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL8021598 | 0.89 | NPSR1 (0.79) | GAANPSR1MAPTLMNAPOLB | |
| Hydrochloric Acid SCHEMBL1831909 | 0.87 | GAA (0.84) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL580813 | 0.86 | ENPP3 (0.70) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL3022016 | 0.85 | GAA (0.71) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL2208521 | 0.85 | GAA (0.80) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL3029240 | 0.85 | GAA (0.80) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL3024303 | 0.85 | MAPT (1.00) | GAANPSR1MAPTLMNAPOLB | |
| SCHEMBL2211235 | 0.85 | GAA (0.80) | GAANPSR1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9316633-B2 | Methods for identifying inhibitors of solute transporters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-19 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2321298-B1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2321298-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017240-A2 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | GAA 2959/4885NPSR1 3589/4885MAPT 2283/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | GAA 2062/4885NPSR1 3001/4885MAPT 1958/4885 |
| US-20110301162-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AURKC, AURKA, CDK1 | GAA 2495/4885NPSR1 3298/4885MAPT 1537/4885 |
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | SLC2A1, SLC2A3, SLC2A8 | GAA 494/4885NPSR1 2816/4885MAPT 1849/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | GAA 2959/4885NPSR1 3589/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.